Abstract
Besides its potent LDL-cholesterol lowering effect, statins have proven to be beneficial
in secondary prevention of myocardial infarction, reduce stroke, and also total mortality.
Although the evidence of a beneficial role in secondary prevention is unequivocal,
their role in primary prevention is still discussed controversially.
Literatur
- 1
Libby P, Crea F.
Clinical Implications of inflammation for cardiovascular primary prevention.
Eur Heart J.
2010;
31
777-783
- 2
The Emerging Risk Factors Collaboration .
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality:
an individual participant meta-analysis.
Lancet.
2010;
375
132-140
- 3
Davignon J.
Beneficial cardiovascular pleiotropic effects of statins.
Circulation.
2004;
109
39-43
- 4
Shepherd J, Cobbe S M, Ford I et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med.
1995;
333
1301-1307
- 5
Downs J R, Clearfield M, Weis S et al.
Primary prevention of acute coronary events with lovastatin in men and women with
average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis
Prevention Study.
JAMA.
1998;
279
1615-1622
- 6
Nakamura H, Arakawa K, Itakura H et al.
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):
a prospective randomised controlled trial.
Lancet.
2006;
368
1155-1163
- 7
Ridker P M, Danielson E, Fonseca F A et al.
Rosuvastatin to prevent events in men and women with elevated C-reactive protein.
N Engl J Med.
2008;
359
2195-2207
- 8
Koenig W, Ridker P M.
Rosuvastatin for primary prevention in patients with European systematic coronary
risk evaluation risk ≥ 5 % or Framingham risk > 20 %: post hoc analyses of the JUPITER
trial requested by European health authorities.
Eur Heart J.
2010;
[Epub ahead of print]
- 9
Genest J, McPherson R, Frohlich J et al.
2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment
of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendation.
Can J Cardiol.
2009;
25
567-579
- 10
Brugts J J, Yetgin T, Hoeks S E et al.
The benefits of statins in people without established cardiovascular disease but with
cardiovascular risk factors: meta-analysis of randomized controlled trials.
BMJ.
2009;
338
b2376
Prof. Dr. Wolfgang Koenig
Universitätsklinikum Ulm
Zentrum für Innere Medizin
Klinik für Innere Medizin II
Albert-Einstein-Allee 23
89081 Ulm
eMail: wolfgang.koenig@uniklinik-ulm.de
